Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice of the 31st Annual General Meeting (AGM). The AGM is scheduled to be held on Tuesday, September 29, 2026, at 04:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for FY2025-26, the reappointment of a director retiring by rotation, and the reappointment of M/s. Goenka Mehta & Associates as statutory auditors for a term of five years.

Biogen Pharmachem Industries Ltd has announced its 31st Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 04:00 P.M. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio Visual Means (OAVM), in compliance with recent regulatory circulars. Key agenda items include the adoption of audited financial statements for the fiscal year ended March 31, 2026, the reappointment of a director retiring by rotation, and the reappointment of M/s. Goenka Mehta & Associates as statutory auditors for a term of five years. The company has also noted that proxy appointments will not be available for this virtual meeting.

Biogen Pharmachem Industries Ltd has informed the exchange that as of June 30, 2026, and currently, there are no unutilized funds remaining from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). Consequently, no information is being provided in Annexure-A as per SEBI regulations. This filing addresses compliance requirements regarding the utilization of proceeds from capital raises.

Biogen Pharmachem Industries Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, considered and approved the unaudited financial results for the quarter ended June 30, 2026. The meeting commenced at 3:15 PM and concluded at 3:35 PM. The financial results have been reviewed by the Audit Committee and approved by the Board. The Statutory Auditors have carried out a limited review. The company operates in a single segment. Previous periods' figures have been re-grouped or re-arranged where necessary.

Biogen Pharmachem Industries Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, approved the un-audited financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and have undergone a limited review by the statutory auditors. The company operates in a single segment. Previous period figures have been re-grouped where necessary.

Biogen Pharmachem Industries Ltd has announced the closure of its trading window for dealing in company securities. The window will be closed from Wednesday, July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the first quarter ended June 30, 2026. This action is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct. The date for the upcoming Board Meeting to consider these financial results will be communicated in due course.

Rama Shiva Lease Finance Pvt Ltd disclosed a change in its shareholding of Biogen Pharmachem Industries Ltd. As per Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, Rama Shiva Lease Finance sold 4,75,00,000 shares, reducing its holding from 9.31% to 4.04% of the total share/voting capital. The transaction was executed through open market. The date of sale is 18.05.2026.

Rama Shiva Lease Finance Pvt Ltd has decreased its shareholding in Biogen Pharmachem Industries Ltd, as disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The company sold 4,75,00,000 shares, reducing its stake from 9.31% to 4.04% of the total share/voting capital. The transaction was executed in the open market on May 18, 2026.

Parichay Infrastructure Ltd. disposed of 3,99,32,000 shares in Biogen Pharmachem Industries Limited, representing 4.42% of the total share capital. This sale reduces Parichay Infrastructure's holding in Biogen Pharmachem to 4,20,68,000 shares, which is 4.66% of the total share capital. The transaction was executed on May 18, 2026, via open market.

Interface Financial Services Ltd. disclosed the sale of 4,03,03,000 shares in Biogen Pharmachem Industries Limited, representing 4.47% of the total share capital. This transaction occurred under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Following the sale, Interface Financial Services Ltd.'s holding in Biogen Pharmachem stands at 4,36,97,000 shares, or 4.84% of the total share capital. The equity share capital of Biogen Pharmachem remains at ₹90,26,03,000.